This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Charles Marwick

JAMA. 1999;282:1509-1510.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington—New methods of controlling the behavior of blood in the human body were reported at the 17th Congress of the International Society on Thrombosis and Hemostasis (ISTH) held here last month. Better treatments for clotting and bleeding disorders were central topics of discussion.

REDUCING CLOT RISK

The risk of venous thromboembolism in surgical patients has long been recognized. Now a new study shows that thromboembolism is also a risk in acutely ill medical patients. But an international, multicenter, randomized, double-blind, placebo-controlled trial has shown that a daily dose of 40 mg of enoxaparin (Lovenox, Rhone-Poulenc Rorer), a low molecular weight heparin, reduced the risk of venous thromboembolism in medically treated patients by about one third.

Meyer-Michel Samama, MD, emeritus professor of hematology at Hôtel Dieu University Hospital in Paris, reported these findings in a presentation at the ISTH Presidential Plenary session. Samama chaired the 11-member group that . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?